Revance Therapeutics (RVNC) Misses Q1 EPS by 7c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
May 9, 2023 4:05 PM EDT
- Q1 total revenue of $49.3 million, a YoY increase of 95.3%.
- Q1 RHA® Collection revenue of $30.3 million, a YOY increase of 45.3%.
- Q1 DAXXIFY® revenue of $15.4 million, driven by PrevU and March launch.
- FDA approves Ajinomoto Biopharma Services, Revances contract manufacturer for DAXXIFY®.
- Fosun Pharmas BLA submission for DaxibotulinumtoxinA for Injection for glabellar lines accepted for review by Chinas National Medical Products Administration (NMPA).
- Conference call and webcast today at 4:30 p.m. ET.
NASHVILLE, Tenn.--(BUSINESS... More
